throbber
1111111111111111 IIIIII IIIII 11111 1111111111 1111111111 111111111111111 11111 1111111111 11111111
`US 20070238860Al
`
`c19) United States
`c12) Patent Application Publication
`SCHLEGL
`
`c10) Pub. No.: US 2007 /0238860 Al
`Oct. 11, 2007
`(43) Pub. Date:
`
`(54) METHOD FOR REFOLDING A PROTEIN
`
`(30)
`
`Foreign Application Priority Data
`
`(76)
`
`Inventor:
`
`Robert SCHLEGL, Wien (AT)
`
`Correspondence Address:
`MICHAEL P. MORRIS
`BOEHRINGER INGELHEIM CORPORATION
`900 RIDGEBURY RD, P. 0. BOX 368
`RIDGEFIELD, CT 06877-0368
`
`(21) Appl. No.:
`
`11/695,950
`
`(22) Filed:
`
`Apr. 3, 2007
`
`(EP) .............................. EP 06112 443
`Apr. 10, 2006
`Publication Classification
`
`(51)
`
`Int. Cl.
`C07K 14147
`(2006.01)
`0~ vs.a ....................................................... ~oo~
`ABSTRACT
`(57)
`
`A method for refolding a protein by mixing a protein
`solution with a refolding buffer at mixing conditions that
`approximate ideal mixing. The method can be carried out
`batch wise, in a fed-batch mode or continuously with on-line
`solubilization of inclusion bodies.
`
`1 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`Patent Application Publication Oct. 11, 2007 Sheet 1 of 6
`
`US 2007 /0238860 Al
`
`Figure 1
`
`en
`(jJ
`"C
`0
`..0
`C
`0 ·;;
`:s
`0
`C ·-"C
`l!j ·(cid:173)-:s
`
`:l
`0
`Cf)
`
`2 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`Addition of folding
`additives (optional)
`Temperature control
`
`Solubilized inclusion
`bodies
`
`~~,;;~~~
`
`Mixer
`
`_ .. __ ; p1ug flow reactor
`
`.,., ........... " , ........ , , .. ,, ...... ······ ..... 'S:2'. , ... , .. ,, ·•·' .... , , ....... ,
`
`Refolding
`tank
`
`Recirculation
`stream
`
`'"T1 -· (C
`C
`aJ
`
`tr,.)
`
`""O
`~ .....
`('D = .....
`t "e -....
`.... 0 = ""O = O" -....
`.... 0 =
`(') ... ....
`
`(')
`
`~ .....
`
`(')
`
`~ .....
`
`0
`
`:-'
`N
`0
`0
`--.J
`
`('D
`
`rJJ =-('D
`.....
`N
`0 ....
`
`O'I
`
`c
`rJJ
`N
`0
`0
`~
`0
`N
`~
`QO
`QO
`O'I
`0
`
`> ....
`
`3 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`Solubilization
`buffer
`
`2
`
`F2,C2
`
`Addition of
`folding additives
`(optional)
`
`~F-1,,C~
`
`-~~ !
`
`3
`
`1
`~esuspended
`inclusion
`bodies
`
`Solubilized
`inclusion bodies
`
`!
`
`.. , ..... , ... , .... ,, .. ,. .... ,, .. ,.2, .... ,,., .. , ..... ,
`
`9
`
`vref
`
`-n
`ta~
`r: ;a
`w
`
`/1\') 10
`
`F5,C5
`
`Refolding
`tank
`
`(')
`
`""O
`~ ....
`('D = ....
`> "e
`"e -....
`~ ....
`.... 0 = ""O = O" -....
`.... 0 =
`0
`:-+-....
`.... ~
`
`(')
`
`~ ....
`
`(')
`
`N
`0
`0
`--.J
`
`rJJ =-('D
`('D ....
`0 ....
`
`(,H
`
`O'I
`
`c
`
`rJJ
`N
`0
`0
`~
`0
`N
`(,H
`QO
`QO
`O'I
`0
`
`> ....
`
`4 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`Patent Application Publication Oct. 11, 2007 Sheet 4 of 6
`
`US 2007 /0238860 Al
`
`Figure 4
`
`E
`
`~J
`j
`,
`250 -]
`! 200 l
`~
`i
`i 150 1
`-e
`j
`l10oj
`~ 501
`
`i
`
`~
`i
`
`tt
`!!
`fl
`I I
`
`native protein
`denatlired and
`redl1c.sid pmtein
`
`~------~
`........ ~~~~~~~ Ii
`i \
`I\
`
`i\
`
`! \
`\
`)
`'-., - ----
`.,,,,.--. , /
`
`I
`I
`i
`:
`,
`I
`
`i
`I
`I
`
`I
`i
`
`'
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`retention time (min)
`
`5 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`Patent Application Publication Oct. 11, 2007 Sheet 5 of 6
`
`US 2007 /0238860 Al
`
`Figure 5
`
`1.0 ~ - - - - - - - - - - - - - - - - - - - - - - - -~
`
`0,8
`
`"O
`Cl)
`5=
`
`O·
`
`0,6
`
`OA f : I
`
`: J
`:I
`
`02
`
`I
`I ........._ fast mix refolding
`I
`I · o · · batch refolding
`I rm "Trm
`fed batch refolding I
`!
`!
`
`0,0 - -~~ -~ -~~ -~ -~ - -~ -~~~~ -~ - -~ . . , . . ,
`200
`500
`600
`100
`300
`400
`0
`Time (min)
`
`6 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`Patent Application Publication Oct. 11, 2007 Sheet 6 of 6
`
`US 2007 /0238860 Al
`
`Figure 6
`
`'"O
`N
`
`~
`' E u
`,,,..
`' 0)

`"O
`M
`'o
`
`'10
`
`8
`
`4
`
`2
`
`0
`
`-2
`
`-6
`
`reference standard
`refolded protein
`denatured protein
`raw data
`
`J'"j,f 7~,~---,A._-, ""'-_-:,.'.~:;'".
`
`:/
`l
`I
`
`200
`
`220
`
`240
`
`260
`
`wavelength (nm)
`
`7 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`US 2007 /0238860 Al
`
`Oct. 11, 2007
`
`1
`
`METHOD FOR REFOLDING A PROTEIN
`
`[0001] This application claims priority benefit to EP 06
`112 443, dated Apr. 10, 2006, the entirety of which is
`incorporated herein.
`[0002] The invention relates to the field of recombinant
`protein production
`[0003] Proteins for industrial applications, e.g. for use as
`biopharmaceuticals or fine chemicals, are either obtained by
`extraction and purification from a natural source, such as a
`plant or animal tissue or microorganisms, or by means of
`recombinant DNA technology.
`[0004] To produce a recombinant protein, the cDNA
`encoding the protein of interest is inserted into an expression
`vector and the recombinant vector is transformed into host
`cells, which are grown to express the protein. The host cells
`may be selected from microorganisms such as bacteria, yeast
`or fungi, or from animal or plant cells.
`[0005] Expression of a recombinant protein is a complex
`event. To obtain the correct conformation, the protein is
`associated with so-called "folding helper proteins" and
`enzymes. The folding helper proteins, also termed "chaper(cid:173)
`ones" or "minichaperones", interact in a complex way so
`that the protein regains its native conformation after passing
`through various intermediate states. Some of the intermedi(cid:173)
`ate states may be quite stable. Enzymes involved in protein
`maturation either catalyze the rapid formation of disulfide
`bridges (1; 2), the isomerization of prolyl-peptide linkages
`(3-6) or more complex modifications, such as the truncation
`of the protein, side chain modifications or modifications of
`the N- and C-terminus. When a protein is efficiently over(cid:173)
`expressed, the production of the nascent peptide chain
`occurs faster than the folding of the protein. For some
`proteins, an intermediate state may also form aggregates (in
`the following, the term "intermediate" forms also encom(cid:173)
`passes aggregate forms). Overall, aggregate formation
`occurs much faster than the complete folding of a protein (7;
`8).
`In expression systems, in which such conditions
`[0006]
`are present, the protein is deposited in the cells in a paracrys(cid:173)
`talline form, so-called "inclusion bodies", also termed
`"refractile bodies".
`[0007] Since the protein, when present in the form of
`insoluble inclusion bodies, is shielded from enzymatic
`attack like proteolysis, it cannot interfere with the physiol(cid:173)
`ogy of the cells. Therefore, recombinant DNA technology
`has taken advantage of this aberrant way of protein secre(cid:173)
`tion, e.g. for the production of the proteins that are toxic for
`the cells (9).
`[0008] Various steps have to be taken to obtain a protein
`from host cells, in which it is accumulated in a denatured
`form, i.e. a conformational state without biological activity,
`in its correctly refolded form. For example, bacterial cells
`carrying inclusion bodies are disintegrated, the inclusion
`bodies harvested by centrifugation and then dissolved in a
`buffer containing a chaotropic agent. The denatured protein
`is then transferred into an environment that favors the
`recovery of its native conformation. Before adopting its
`native state, the protein undergoes a transition through
`various semi-stable intermediates. Since intermediates in the
`early stages of the folding pathway have highly exposed
`hydrophobic domains, which are prone to associate, they
`tend to form aggregates. Obviously, intramolecular interac-
`
`tions are concentration-independent, whereas intermolecular
`interactions are concentration-dependent. The higher the
`protein concentration, the higher the risk of intermolecular
`misfolding, and vice versa. In principle, refolding, also
`termed "renaturation", may be considered as a race against
`aggregate formation, which usually follows second or higher
`order reaction kinetics, while refolding of the protein fol(cid:173)
`lows first order reaction kinetics (10).
`[0009] A protein can be refolded from its denatured con(cid:173)
`formation to the correctly folded conformation by transfer(cid:173)
`ring it into an environment that favors the change to the
`native conformation. During this rearrangement, the protein
`passes through several intermediate conformational states,
`which are prone to form aggregates. Depending on the
`individual protein and on the environmental conditions, the
`aggregates may precipitate. Independent of whether the
`aggregates remain soluble or whether they precipitate, this
`process leads to dramatic losses in the yield of correctly
`folded protein.
`[0010] During a folding reaction, several characteristic
`conformations are formed. Although the transition from one
`conformation to another is smooth and a characterization of
`the distinct conformations is not available yet, similar states
`have been reported for different proteins. Immediately after
`initiation of the folding reaction, the unfolded protein col(cid:173)
`lapses and a partly structured intermediate state is formed.
`This change in conformation is called burst phase and
`appears in the sub millisecond time scale. Rapid changes in
`spectroscopic properties, such as fluorescence and far UV(cid:173)
`CD are due to the molecular collapse of the protein. For
`lysozyme, molecular compaction and formation of globular
`shape was detected with small angle X-ray scattering and
`tryptophan fluorescence (11). Other examples of proteins
`where a burst phase was detected are ovalbumin (12), barstar
`(13), cytochrom C (14), dihydrofolat reductase (15) and
`a-lactalbumin (16). After the burst phase, a more compact
`structure is formed, the 'molten globule' intermediate. The
`molten globule is defined as state with native-like secondary
`structure but fluctuating tertiary structure (17). It was pro(cid:173)
`posed as a common intermediate in folding pathways and a
`number of proteins pass through a molten globule structure
`during folding. Intermediates in early folding steps cannot
`be detected, either due to very rapid or very little structural
`changes. In later folding events, reorganization of tertiary
`contacts takes place. These reactions are slow compared to
`formation of secondary and tertiary structure. They com(cid:173)
`prise generation and reshuffling of disulfide bonds, praline
`isomerization and domain pairing. Disulfide bond interme(cid:173)
`diates can be detected for example with reversed phase
`chromatography. Association of native monomers to bio(cid:173)
`logically active oligomers is the final step in the case of
`larger proteins.
`[0011] With some currently available methods, refolding
`of proteins is achieved either by diluting the protein in a
`refolding buffer in a batch or continuous mode (18-20). In
`these methods, batch wise dilution results in highly diluted
`protein solutions and therefore large process volume, which
`often is the bottleneck in industrial processes.
`In another approach the naturally occurring folding
`[0012]
`pathway is simulated by adding chaperons and/or minichap(cid:173)
`erons, and/or enzymes that catalyze certain steps in the in
`vivo folding pathway (2; 21-25). Complex refolding reactor
`systems comprising series of tanks have been designed to
`improve the refolding reaction (26).
`
`8 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`US 2007 /0238860 Al
`
`Oct. 11, 2007
`
`2
`
`[0013]
`In another approach, the helper proteins and
`enzymes are immobilized to a solid phase. Then the protein
`solution is passed over a so-called "Packed Bed" that
`contains the immobilized helper proteins and/or helper
`enzymes, whereby the protein is folded into its native
`conformation (27-30). Since the folding helper proteins and
`enzymes must be present in a stoichiometric ratio, this
`process requires almost the same amount of helper proteins,
`which in tum have to be produced by recombinant DNA
`technology, as the finally obtained protein of interest. In
`addition, to improve folding, the helper proteins are usually
`fused to the protein of interest, which requires further
`processing of the fusion protein. For these reasons, this
`strategy is very cost intensive and not applicable on an
`industrial scale.
`[0014] WO 02/057296 discloses an on-line method for
`refolding a protein by dilution and subsequent separation.
`The solution containing unfolded protein is diluted with
`refolding buffer by mixing in a mixing chamber and the
`output of this dilution step is directly loaded onto the
`separation device, e.g. a chromatographic colunm. By
`optionally varying the length of the tubing between the
`mixing chamber and the colunm, the time for refolding the
`protein in solution-before it is bound to the colunm----can
`be adjusted. This system is limited to proteins with fast
`refolding kinetics and to proteins with low requirements as
`regards adjusting the conditions of the separation step to
`those of the antecedent refolding step.
`[0015] Dilution of the unfolded protein with the refolding
`buffer using a flow-type reactor was described by Terashima
`et al (31): Denatured lysozyme is continuously diluted in a
`small mixing unit and directed to a packed colunm with a
`flow that closely approaches a plug flow. The achieved
`refolding efficiencies in the flow type reactor are hardly
`superior to those of a batch system.
`[0016] Among the known refolding strategies, dilution is
`still the simplest methodology. In industrial scale applica(cid:173)
`tions, dilution is commonly used for refolding of recombi(cid:173)
`nant proteins, expressed as inclusion bodies. Typically,
`dilution is carried out in one step by mixing/diluting the
`solution containing solubilized protein with a diluent con(cid:173)
`taining a solubilizing agent in an amount necessary to reach
`the optimal level of dilution. When the concentration of
`solubilizing agent is below a certain threshold level, the
`protein start to regain its biologically active three-dimen(cid:173)
`sional conformation. Depending on the specific protein and
`the chosen folding conditions, refolding begins within mil(cid:173)
`liseconds to seconds. In this initial burst phase, the protein
`is highly susceptible to aggregation. To minimize aggrega(cid:173)
`tion, the protein concentration has to be kept low. After this
`initial refolding phase, the protein forms into a more com(cid:173)
`pact structure. This intermediate structure, which is some(cid:173)
`times termed 'molten globule', is defined as a state with a
`secondary structure that resembles that of the native protein
`and that is less susceptible to aggregation. Complete refold(cid:173)
`ing, including formation of disulfide bonds, praline isomer(cid:173)
`ization and domain pairing may take hours and up to several
`days.
`[0017] Usually, such dilution is carried out as a so-called
`"batch" dilution, in which the diluent is added in a defined
`volume, the "batch", to the unfolded protein solution. Batch
`dilution has many disadvantages when carried out at large
`scale. In commercial protein purification methods, depend(cid:173)
`ing on the dilution rate, the total volumes being handled at
`
`the same time can be very large, usually between several
`hundreds or thousand liters. In such processes, variations in
`refolding efficiency are caused by ill-defined operating vari(cid:173)
`ables with regard to feed rate and mixing, which result in
`non-robust processes during scale-up with (32).
`[0018] During batch refolding, all of the protein in the
`reactor is transiently present in the form of reactive inter(cid:173)
`mediates, resulting in a brief period of aggregation. There(cid:173)
`fore, optimum operation occurs at extremely low overall
`protein concentration. Additionally, refolding a protein in
`large volumes by batch dilution may cause some re-aggre(cid:173)
`gation of the protein, probably because the solution, at least
`as initially present in batch dilutions, is not homogeneous.
`This may result in a lower net yield of refolded protein. The
`non-homogeneity of the solution in batch dilutions results
`from the difficulty in timely achieving "ideal" mixing con(cid:173)
`ditions, which are required for obtaining homogeneity, in
`large volumes.
`[0019]
`Ideal mixing conditions in a refolding mixture are
`given when the composition of the mixture with respect to
`its physical-chemical properties is identical at each time
`interval for each infinite small volume element in the
`refolding tank. In theory, "ideal" mixing conditions result in
`a homogenous solution without concentration gradients of
`unfolded or partially refolded protein during dilution. Ideal
`mixing conditions are a function of a solution's "mixing
`time". Mixing time is the time needed for the molecules in
`a droplet between addition of the droplet to the solution and
`their even dispersion in the total volume of the solution.
`Variables affecting mixing time include the total volume of
`the solution, the size of the added volume, the size and
`configuration of the mixing chamber (vessel, tank), and
`other characteristics of the mixing device, e.g. whether
`stirring occurs and which type of stirrer is used, and the
`location of the inlets in the mixing chamber. The larger the
`volume of the solution and the larger the size of the reaction
`vessel, the longer is the mixing time and thus the longer it
`takes until the mixture, e.g. the solubilized protein solution
`and the diluent; will not be homogenous. As reported by
`Ram et al. (33), mixing time in process vessels used in
`biopharmaceutical manufacturing can last up to several
`minutes.
`[0020] Due to the concentration gradient present in a
`non-homogenous solution, there are variations of the pH
`value and ionic strength, which results in variations of the
`charges of the unfolded or partially folded protein causing
`the protein to refold incorrectly or interact improperly with
`nearby protein molecules. A high local concentration of
`unfolded protein in the regions of the mixing chamber where
`the unfolded protein is fed into the reactor, may lead to
`higher aggregation compared to an "ideal" mixing chamber.
`[0021]
`In so-called "fed-batch" processes, the unfolded
`protein is added to the refolding tank in a semi-continuous
`or pulse wise manner, which results in a lower actual
`concentration of folding intermediates and therefore less
`aggregation (34). Such methods have the advantage that the
`actual concentration of unfolded protein is kept low, while
`the final concentration of refolded protein can be increased.
`The composition in terms of the protein's state in the
`refolding mixture changes from the first molecule (virtual
`isolation, best chance of successful folding into native
`conformation) to the last molecule, which is added to a
`volume containing the correctly folded or misfolded proteins
`(worst chance of successful refolding). Like in batch meth-
`
`9 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`US 2007 /0238860 Al
`
`Oct. 11, 2007
`
`3
`
`ods, renaturation that is conducted pulse-wise (fed-batch
`mode) can be only operated in a discontinuous way. In a
`fed-batch reactor, the amount of denaturing and reducing
`agents from the feed solution start to accumulate during
`addition of the unfolded protein until they reach a critical
`level at which the protein starts to unfold. Design equations
`for fed-batch refolding with regard to the folding and
`aggregation kinetics have been described by Dong et al. (35)
`and Kotlarsky et al. (36).
`It was an object of the invention to provide an
`[0022]
`improved method for obtained a protein in its refolded,
`biologically active form.
`[0023] The solution of the problem underlying the inven(cid:173)
`tion is based on refolding the protein under defined mixing
`conditions.
`[0024] The present invention relates to a method for
`obtaining a biologically active recombinant protein by
`reconstituting the protein from a denatured state to its active
`form, said method containing a steps of mixing a feed
`solution containing the protein in its denatured form and/or
`its biologically inactive intermediate forms with a refolding
`buffer under conditions that approximate ideal mixing,
`wherein
`i. the mixing time is ca. 1 msec to ca. 10 sec; and
`[0025]
`ii. the dilution rate F p:F B
`is ca. 1: 1 to ca.
`[0026]
`1: 100000, wherein
`[0027] F Pis the flow rate of said protein feed solution
`and
`[0028] F B is the flow rate of said refolding buffer.
`"Denatured form", in the meaning of the present
`[0029]
`invention, designates the biologically inactive, unfolded or
`predominantly misfolded form of the expressed protein of
`interest, as obtained as a product of the recombinant pro(cid:173)
`duction process, e.g. as obtained after dissolving the inclu(cid:173)
`sion bodies.
`"Intermediate forms" or "intermediates" in the
`[0030]
`meaning of the present invention, designates the forms that
`the protein passes through between its denatured form and
`its reconstituted (refolded) native and biologically active
`state. The intermediates, which are biologically inactive or
`have a lower biological activity than the native protein, may
`form aggregates.
`[0031] A "protein" in the meaning of the present invention
`is any protein, protein fragment or peptide that requires
`refolding upon recombinant expression in order to obtain
`such protein in its biologically active form.
`[0032] Preferred mixing times range from ca. 10 msec and
`ca. 5 sec, preferably from ca. 100 msec to ca. 1 sec.
`[0033] By maintaining a very high flow rate of the refold(cid:173)
`ing buffer and a low flow rate of the feed stream containing
`the unfolded protein, the method of the invention provides
`very high local dilution rates; preferred dilution rates range
`from 1:5 to 1:50000 and from 1:10 to 1:10000.
`[0034] Depending on the dimensions of the system, the
`flow rates may vary within a wide range, e.g. from µUmin
`in the case of laboratory scale to Liters/min in the case of
`industrial scale manufacturing.
`[0035] The concentration of the protein after dilution with
`refolding buffer is in the range of ca. 1 ng/ml to 10 mg/ml,
`for example ca. 100 ng/ml to ca. 5 mg/ml or ca. 1 µg/ml to
`ca. 1 mg/ml.
`[0036] The refolding buffer used for a given protein of
`interest is customized to the refolding requirements/kinetics
`of that protein. Refolding buffers are known in the art and
`
`commercially available; typical buffer components are gua(cid:173)
`dinium chloride, dithiothreitol (DTT) and optionally a redox
`system ( e.g. reduced glutathione GSH/oxidized glutathione
`GSSG), EDTA, detergents, salts, and refolding additives like
`L-arginine.
`[0037] As mentioned above, "ideal mixing" refers to con(cid:173)
`ditions that result in a homogenous solution without sub(cid:173)
`stantial concentration gradients in solution. By ideal mixing,
`infinitive short mixing times are achieved.
`[0038] Since the mixing conditions according to the
`method of the invention are close to ideal mixing, mixing of
`the protein feed stream with the refolding buffer occurs with
`similar or faster kinetics than the unfolding/aggregation
`kinetics of the protein, thereby reducing or completely
`preventing aggregation of the protein
`In the process of the invention, the actual protein
`[0039]
`concentration immediately after mixing is much lower as
`compared to conventional refolding methods.
`In its simplest embodiment, the method of the
`[0040]
`invention is a batch process that comprises, as its essential
`step, the above-defined mixing operation, in which a feed
`stream having a high concentration of unfolded protein and
`a low flow rate is combined with a refolding buffer solution
`having a high flow rate.
`[0041] This embodiment of the invention, which is sche(cid:173)
`matically shown in FIG. 1, is particularly useful for proteins
`that have very fast refolding kinetics, e.g. peptides and
`smaller protein fragments. The refolding buffer and the
`protein feed solution are independently fed from reservoirs
`to the mixing device. Having passed the mixing device, the
`highly diluted solution containing the refolded protein is
`collected in a tank. Optionally, before entering the tank,
`refolding additives may be added in the case of proteins that
`have not yet completely refolded during mixing to suppress
`or completely prevent unfolding/aggregation. Compounds
`useful as refolding additives are known in the art, examples
`are L-arginine, Tris, detergents, redox systems like GSH/
`GSSG, ionic liquids like N'-alkyl and N'-(omega-hydroxy(cid:173)
`alkyl)-N-methylimidazolium chlorides etc. The end of the
`process is reached when the reservoir of refolding buffer
`and/or protein solution is exhausted. At this point, the feed
`of unfolded protein (or the feed of buffer, respectively) is
`interrupted and the solution containing the protein in its
`refolded, biologically active form is withdrawn from the
`tank. In this embodiment of the invention, it is advantageous
`to have the mixing device equipped with means that control
`the temperature to exclude any, even minimal aggregation,
`e.g. cooling means.
`[0042] Mixing devices suitable for use in the method of
`the invention are any mixers that ensure fast mixing and
`short mixing times, e.g. tubular jet mixers or static mixers,
`e.g. commercially available mixers from Fluitec, CH, or
`Sulzer Chemtech, CH. In the simplest form of the method of
`the invention, the two streams can be combined into one
`stream by a branch connection without any additional spe(cid:173)
`cific mixing devices. Such a simple device can be used to
`achieve the desired mixing efficiency, albeit without precise
`control of mixing efficiency. In the case that the mixer is a
`high-throughput continuous flow device, accurate control of
`the flows is of particular importance. With such mixers,
`mixing times as low as a few milliseconds on the small scale
`or a few seconds on the large scale can be achieved. The
`mixing characteristics of such mixers most closely approxi(cid:173)
`mate "ideal mixing". The mixing ratio of the two streams is
`
`10 of 13
`
`Fresenius Kabi
`Exhibit 1022
`
`

`

`US 2007 /0238860 Al
`
`Oct. 11, 2007
`
`4
`
`adjusted such that a low protein concentration is maintained
`to minimize aggregation. After mixing the two streams, the
`protein starts to refold.
`[0043] The method of the invention is also referred to as
`"fast mix refolding".
`[0044] Except for proteins with fast refolding kinetics,
`which may already be completely refolded during mixing,
`the initial refolding steps take place in the mixing device and
`refolding is completed in the refolding tank or in the
`optionally present adjustment zone, e.g. in the plug flow
`reactor (PFR), as described below.
`In a further embodiment, the method of the inven(cid:173)
`[0045]
`tion comprises in addition, subsequent to the mixing step
`defined above and before the solution enters the refolding
`tank, a step in which the highly diluted mixture is transferred
`to a zone in which the protein is allowed to form more stable
`folding intermediates under precisely controlled conditions
`such that unfolding and formation of aggregates is sup(cid:173)
`pressed or completely prevented. This step is also referred to
`as "adjustment step", and the zone or the reactor in which
`adjustment occurs is referred to as "adjustment zone" or
`"adjustment reactor", respectively.
`In a preferred embodiment, the adjustment reactor
`[0046]
`is a plug flow reactor, i.e. a chemical reactor where the fluid
`passes through in a coherent manner, so that the residence
`time is the same for all elements. An ideal plug flow reactor
`has a fixed residence time:
`[0047] Any fluid that enters the reactor at time twill exit
`the reactor at time t+i:, where i: is the residence time of the
`reactor. In its simplest form, the plug flow reactor is a tube,
`optionally packed with solid material.
`[0048] The adjustment step provides the possibility of
`generating, for a defined volume and period of time, con(cid:173)
`ditions that favor stabilization of the partially refolded
`protein. This may be achieved by a short-term change of the
`pH value (increase or decrease) and/or change of the tem(cid:173)
`perature (heating or cooling) and/or addition of refolding
`additives, as defined above, in the adjustment zone. The
`adjustment step provides the advantage that optimal refold(cid:173)
`ing conditions, e.g. heating or cooling or addition of addi(cid:173)
`tives, need to applied only to a small volume as compared
`to the refolding tank, thus saving energy, reagents and costs.
`[0049] The mean residence time, i.e. the time that it takes
`for the solution to pass through the adjustment reactor, i.e.
`the tube in the case of a plug flow reactor, depends on the
`flow rate and the tube volume. The residence time should be
`long enough to allow the protein to fold into a more compact
`and stable structure, e.g. into a so-called 'molten globule'
`intermediate.
`[0050] By varying the design of the adjustment reactor,
`e.g. length and/or diameter of the tube, the residence time of
`a specific protein in the adjustment zone and thus its
`exposure to the selected adjustment conditions is adapted to
`the requirements of the protein, i.e. its specific refolding
`kinetics. In the case of fast refolding kinetics, refolding is
`usually completed already in the adjustment zone.
`[0051] After leaving the adjustment zone, the protein
`solution containing the refolded protein and/or the partially
`refolded stabilized intermediates is collected in the refolding
`tank, where, if still necessary, refolding is completed.
`In the embodiment that provides an adjustment
`[0052]
`step, the method of the invention may be conducted batch(cid:173)
`wise or preferably, by recycling the protein solution from the
`refolding tank, in the fed-batch mode.
`
`In the batch mode, the end of the process is reached
`[0053]
`when the reservoir of refolding buffer and/or protein solu(cid:173)
`tion is exhausted. At this point, the feed of unfolded protein,
`or of the refolding buffer, respectively, is interrupted and the
`protein solution is withdrawn from the tank. FIG. 2 shows
`the schematic drawing of the embodiment of the invention
`that is a fed-batch process comprising an adjustment step in
`combination with recycling of the protein solution. In this
`embodiment, the protein solution circulates at high flow
`rates from the refolding tank back to the feed inlet, where
`unfolded protein is freshly introduced into the system. In
`such embodiment, the recycled protein solution forms the
`refolding buffer solution.
`In a preferred embodiment, the method of the
`[0054]
`invention is performed on-line and, even more preferred, in
`a continuous mode. "On-line" means that refolding is con(cid:173)
`nected to one or more other steps, e.g. antecedent steps, of
`the overall process, e.g. solubilization of inclusion bodies.
`[0055] By running refolding continuously and on-line
`with solubilization of inclusion bodies, as depicted in FIG.
`3, time consumption and costs can be reduced and the yield
`of refolded protein increased as compared to known meth(cid:173)
`ods. The method of the invention ensures, in particular in its
`continuous on-line embodiment, fast and efficient process(cid:173)
`ing of inclusion body proteins, thereby reducing inadvertent
`variations, such as variations in refolding efficiency or
`product homogeneity. On-line solubilization of suspended
`inclusion bodies is preferred to their batch-wise solubiliza(cid:173)
`tion in a stirred tank, where the contact time between the
`molecules and the solubilizing agent has to be minimized or
`precisely controlled to avoid irreversible modification of the
`proteins. This is often the case when solubilization of the
`inclusion bodies is carried out at extreme pH values. Such
`irreversible modification of amino acid side chains could
`lead to reduced activity of the molecule.
`[0056] Exemplified by the embodiments in which the
`protein solution is recycled (FIGS. 2 and 3), very high local
`dilution rates (1: 1000, 1: 10000 or more) can be easily
`achieved depending on the ratio of the flow rate of the
`solution of unfolded protein F B (designated F3 in the Figure)
`and the flow rate of the circulating refolding buffer F B
`( designated F 5 in the figure). The protein concentration C4
`after
`dilution can be calculated by a simple mass balance as
`
`[0057] C3 is the concentration of the unfolded protein in
`the feed stream and C4 is the concentration of unfolded
`protein immediately after mixing. The flow rate of the
`circulating stream necessary to achieve the desired concen(cid:173)
`tration of unfolded protein after dilution (C4 ) can be simply
`calculated by neglecting C5 (refolded protein present in the
`reaction system, which is less susceptible to aggregation) as
`
`F 5~((C3xF3 )/C4 )-F3
`[0058] The tota

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket